LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances) • Delaware
THIS LICENSE AGREEMENT (“Agreement”) is entered into as of March 30, 2022 (the “Effective Date”), by and between InnoBation Bio Co., Ltd., a Korean company (“LICENSOR”) and Valetudo Therapeutics LLC, a Delaware company (“LICENSEE”).
ASSIGNMENT OF CONTRACTAssignment of Contract • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
This Assignment Agreement is entered into as of October 1, 2022 by and between Valetudo Therapeutics LLC, a Delaware limited liability company (“Assignor”) and Liminatus Pharma, LLC, a Delaware limited liability company (“Assignee”) (the “Parties”).
ASSIGNMENT OF CONTRACTLicense and Development Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
This Assignment is entered into as of April 10, 2020 by and between Viral Gene, Inc., a Delaware corporation (“Assignor”) and Liminatus Pharma, LLC, a Delaware limited liability company (“Assignee”) (the “Parties”).
Amendment to the LICENSE AND DEVELOPMENT AGREEMENT Between Targeted Diagnostics & Therapeutics, Inc. and Viral Gene, Inc. Dated September 8, 2016License and Development Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
This Amendment (“Amendment’), effective November 1, 2016, is made by and between Targeted Diagnostics & Therapeutics, Inc. (“TDT”) and Viral Gene, Inc. (“VG”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
THIS AGREEMENT, dated as of January l, 1999, is by and between THOMAS JEFFERSON UNIVERSITY (“.TJU”), a not-for-profit corporation, formed under the laws of the Commonwealth of Pennsylvania, and having its principal place of business at 11th and Walnut Streets, Philadelphia, Pennsylvania 19107, and Targeted Diagnostics & Therapeutics, Inc. (“TDT”), a corporation organized under the laws of the Commonwealth of Pennsylvania, and having its principal place of business at 728 Lancaster Avenue, Exton, PA 19341.
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 8th, 2023 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances) • Pennsylvania
THIS LICENSE AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into as of June 10, 2018 (the “Effective Date”) between Liminatus Pharma, LLC, a Delaware limited liability company (“LIMINATUS”), and Targeted Diagnostics & Therapeutics, Inc. (“TDT”). LIMINATUS and TDT may each individually be referred to herein as a “Party” and may together be referred to herein as the “Parties.”
